124 related articles for article (PubMed ID: 10564391)
21. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
22. Pathological and genetic correlates of apoptosis in the progression of colorectal neoplasia.
Hawkins N; Lees J; Hargrave R; O'Connor T; Meagher A; Ward R
Tumour Biol; 1997; 18(3):146-56. PubMed ID: 9143411
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis and expression of bcl-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung.
Zirbes TK; Lorenzen J; Baldus SE; Moenig SP; Wolters U; Ottlik A; Thiele J; Hölscher AH; Dienes HP
Histopathology; 1998 Aug; 33(2):123-8. PubMed ID: 9762544
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
25. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
26. Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer.
Kaklamanis L; Savage A; Whitehouse R; Doussis-Anagnostopoulou I; Biddolph S; Tsiotos P; Mortensen N; Gatter KC; Harris AL
Br J Cancer; 1998 Jun; 77(11):1864-9. PubMed ID: 9667660
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2.
Buglioni S; D'Agnano I; Cosimelli M; Vasselli S; D'Angelo C; Tedesco M; Zupi G; Mottolese M
Int J Cancer; 1999 Dec; 84(6):545-52. PubMed ID: 10567896
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival.
Ofner D; Riehemann K; Maier H; Riedmann B; Nehoda H; Tötsch M; Böcker W; Jasani B; Schmid KW
Br J Cancer; 1995 Oct; 72(4):981-5. PubMed ID: 7547253
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma.
Manne U; Myers RB; Moron C; Poczatek RB; Dillard S; Weiss H; Brown D; Srivastava S; Grizzle WE
Int J Cancer; 1997 Jun; 74(3):346-58. PubMed ID: 9221816
[TBL] [Abstract][Full Text] [Related]
30. mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer.
Paradiso A; Ranieri G; Simone G; Silvestris N; Costa A; De Lena M; Leone A; Vallejo C; Lacava J
Oncology; 2002; 62(3):278-85. PubMed ID: 12065876
[TBL] [Abstract][Full Text] [Related]
31. The correlation between IGF-II and Bcl-2 expression in colorectal adenocarcinoma.
Zhang MS; Hu AH; Qiu H; Xiong HH; Chen Y
Med Oncol; 2012 Jun; 29(2):928-32. PubMed ID: 21380782
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma.
Sun XF; Carstensen JM; Zhang H; Stål O; Wingren S; Hatschek T; Nordenskjöld B
Lancet; 1992 Dec; 340(8832):1369-73. PubMed ID: 1360088
[TBL] [Abstract][Full Text] [Related]
33. Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment.
Maluf FC; Cordon-Cardo C; Verbel DA; Satagopan JM; Boyle MG; Herr H; Bajorin DF
Ann Oncol; 2006 Nov; 17(11):1677-86. PubMed ID: 16984978
[TBL] [Abstract][Full Text] [Related]
34. The role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma.
Palazzo JP; Kafka NJ; Grasso L; Chakrani F; Hanau C; Cuesta KH; Mercer WE
Hum Pathol; 1997 Oct; 28(10):1189-95. PubMed ID: 9343326
[TBL] [Abstract][Full Text] [Related]
35. Expression of mdm2 and p53 in epithelial neoplasms of the colorectum.
Hao XP; Günther T; Roessner A; Price AB; Talbot IC
Mol Pathol; 1998 Feb; 51(1):26-9. PubMed ID: 9624416
[TBL] [Abstract][Full Text] [Related]
36. Programmed cell death in colorectal carcinogenesis.
Valentini AM; Caruso ML; Armentano R; Pirrelli M; Rizzi E; Lapenna F; Renna L
Anticancer Res; 1999; 19(4B):3019-24. PubMed ID: 10652586
[TBL] [Abstract][Full Text] [Related]
37. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of the immunohistochemical aspects of tumor suppressor genes p53, bcl-2, PTEN and nuclear proliferative antigen Ki-67 in resected colorectal carcinoma.
Ghiţă C; Vîlcea ID; Dumitrescu M; Vîlcea AM; Mirea CS; Aşchie M; Vasilescu F
Rom J Morphol Embryol; 2012; 53(3):549-56. PubMed ID: 22990545
[TBL] [Abstract][Full Text] [Related]
39. Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas.
Broll R; Stark A; Windhövel U; Best R; Strik MW; Schimmelpenning H; Schwandner O; Kujath P; Bruch HP; Duchrow M
Eur J Cancer; 1999 Jul; 35(7):1083-8. PubMed ID: 10533452
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of apoptosis in breast cancer (pT1-pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical study.
Sirvent JJ; Aguilar MC; Olona M; Pelegrí A; Blázquez S; Gutiérrez C
Histol Histopathol; 2004 Jul; 19(3):759-70. PubMed ID: 15168338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
